Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III immunogenicity comparison of a recombinant 9-valent HPV vaccine versus Gardasil 9 in women aged 16-26 years
CTR20222154Phase 3Active
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus 9-valent virus-like particle vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma, vaginal cancer, anal cancer, sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Started Sep 2022; status: active.
02
Drugs
human papillomavirus 9-valent virus-like particle vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on CTR20222154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222154.